Cannabinoid CB2 receptor: a new target for controlling neural cell survival?

Trends in Pharmacological Sciences

Volumn 28, Issue 1, 2007, Pages 39-45

  Fernández Ruiz, Javier ^a   Romero, Julián ^b   Velasco, Guillermo ^a   Tolón, Rosa M ^b   Ramos, José A ^a   Guzmán, Manuel ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; CANNABINOID; CANNABINOID 2 RECEPTOR; CERAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CELL ACTIVATION; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL ANALYSIS; DEGENERATIVE DISEASE; GLIOMA; HUMAN; NERVE CELL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; UPREGULATION; XENOGRAFT; ANIMAL; ASTROCYTE; CYTOLOGY; DRUG EFFECT; METABOLISM; MICROGLIA;

ANIMALS; ASTROCYTES; CELL SURVIVAL; HUMANS; MICROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; RECEPTOR, CANNABINOID, CB2;

EID: 33845959991     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2006.11.001     Document Type: Review

References (60)

1. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 4 (2003) 873-878
2. Mackie K. Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 101-122
3. Guzmán M., et al. Cannabinoids and cell fate. Pharmacol. Ther. 95 (2002) 175-184
4. Romero J., et al. The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. Pharmacol. Ther. 95 (2002) 137-152
5. Guzmán M. Cannabinoids: potential anticancer agents. Nat. Rev. Cancer 3 (2003) 745-755
6. Pertwee R.G. Pharmacological actions of cannabinoids. Handb. Exp. Pharmacol. 168 (2005) 1-51
7. Fernández-Ruiz J., et al. Cannabinoids in neurodegeneration and neuroprotection. In: Mechoulam R. (Ed). Cannabinoids as Therapeutics (2005), Birkhaüser, Switzerland 79-109
8. 2 selective ligands. Curr. Med. Chem. 12 (2005) 1217-1237
9. Howlett A.C., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
10. 2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. 237 (1996) 704-711
11. 2 receptor-dependent mechanism. Mol. Pharmacol. 65 (2004) 999-1007
12. 2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J. 20 (2006) 2405-2407
13. 2 and multiple signal transduction pathways. FEBS Lett. 577 (2004) 563-569
14. 2 receptor-induced apoptosis of human leukaemia cells. FEBS Lett. 579 (2005) 5084-5088
15. Molina-Holgado E., et al. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol 3-kinase/Akt signaling. J. Neurosci. 22 (2002) 9742-9753
16. 2 cannabinoid receptors in mast cells. J. Immunol. 170 (2003) 4953-4962
17. 2 cannabinoid receptor. Cancer Res. 61 (2001) 5784-5789
18. Carracedo A., et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9 (2006) 301-312
19. Carracedo A., et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 66 (2006) 6748-6755
20. Sugiura T., et al. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog. Lipid Res. 45 (2006) 405-446
21. Mechoulam R., and Hanus L. A historical overview of chemical research on cannabinoids. Chem. Phys. Lipids 108 (2000) 1-13
22. Eljaschewitsch E., et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49 (2006) 67-79
23. Huffman J.W. CB2 receptor ligands. Mini Rev. Med. Chem. 5 (2005) 641-649
24. 2, a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 14228-14233
25. 2 cannabinoid receptor-mediated peripheral antinociception. Pain 93 (2001) 239-245
26. Lynn A.B., and Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J. Pharmacol. Exp. Ther. 268 (1994) 1612-1623
27. Stella N. Cannabinoid signaling in glial cells. Glia 48 (2004) 267-277
28. Maresz K., et al. Modulation of the cannabinoid CB receptor in microglial cells in response to inflammatory stimuli. J. Neurochem. 95 (2005) 437-445
29. Skaper S.D., et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 3984-3989
30. Ross R.A., et al. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 40 (2001) 221-232
31. 2) on sensory nerve fibers and adnexal structures in human skin. J. Dermatol. Sci. 38 (2005) 177-188
32. Wotherspoon G., et al. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135 (2005) 235-245
33. 2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur. J. Neurosci. 23 (2006) 1530-1538
34. 2 receptors. Science 310 (2005) 329-332
35. 2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 53 (2004) 208-213
36. 2 peripheral cannabinoid receptors during B-cell differentiation. Blood 92 (1998) 3605-3615
37. 9-Tetrahydrocannabinol inhibits human breast cancer cell cycle by down-regulating Cdc2. Cancer Res. 66 (2006) 6615-6621
38. 2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood 104 (2004) 526-534
39. Mechoulam R., et al. Cannabinoids and brain injury: therapeutic implications. Trends Mol. Med. 8 (2002) 58-61
40. 2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 23 (2003) 11136-11141
41. Benito C., et al. A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J. Neurosci. 25 (2005) 2530-2536
42. Fernández-Lopez D., et al. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatr. Res. 60 (2006) 169-173
43. Lastres-Becker I., et al. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 19 (2005) 96-107
44. Lastres-Becker I., et al. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. NeuroReport 15 (2004) 2375-2379
45. Ramirez B.G., et al. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25 (2005) 1904-1913
46. 2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur. J. Pharmacol. 542 (2006) 100-105
47. Arévalo-Martin A., et al. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. 23 (2003) 2511-2516
48. Pryce G., et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126 (2003) 2191-2202
49. Facchinetti F., et al. Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lypopolysaccharide. Glia 41 (2003) 161-168
50. Puffenbarger R.A., et al. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 29 (2000) 58-69
51. Molina-Holgado F., et al. Anandamide suppresses nitric oxide and TNF-α responses to Theiler's virus or endotoxin in astrocytes. NeuroReport 8 (1997) 1929-1933
52. 2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J. Neurosci. Res. 67 (2002) 829-836
53. Sheng W.S., et al. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1β-stimulated human astrocytes. Glia 49 (2005) 211-219
54. Molina-Holgado F., et al. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci. 23 (2003) 6470-6474
55. Walter L., et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 23 (2003) 1398-1405
56. Velasco G., et al. Hypothesis: cannabinoid therapy for the treatment of gliomas?. Neuropharmacology 47 (2004) 315-323
57. Galve-Roperh I., et al. Antitumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 6 (2000) 313-319
58. Casanova M.L., et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest. 111 (2003) 43-50
59. Blázquez C., et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J. 17 (2003) 529-531
60. Blázquez C., et al. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 64 (2004) 5617-5623